m6A甲基转移酶KIAA1429在恶性肿瘤中的作用及研究进展
The Role and Research Progress of m6A Methyltransferase KIAA1429 in Malignant Tumors
DOI: 10.12677/ACM.2022.125578, PDF,   
作者: 王 昊, 吴若卿, 李 铀, 肖 辉*：哈尔滨医科大学附属第二医院，黑龙江 哈尔滨
关键词: KIAA1429；m6A甲基转移酶；恶性肿瘤；靶点；KIAA1429； m6A Methyltransferase； Malignant Tumors； Target
摘要: N6-甲基腺嘌呤(m6A)修饰是真核信使RNA (mRNA)上最普遍的内部修饰之一，它也参与了各种RNA相关功能，尤其是在人类恶性肿瘤发生发展的过程中发挥着重要作用。作为一种动态且可逆的修饰，m6A的表达水平受m6A甲基转移酶、去甲基酶及m6A结合蛋白的共同调节。目前已发现的甲基转移酶主要有METTL3、METTL14、KIAA1429 (VIRMA)、WTAP等。目前多篇文献报道了m6A甲基转移酶KIAA1429可促进癌症的进展，并与癌症的低生存率具有一定的相关性，如乳腺癌、肝癌和肾癌等。本文总结了KIAA1429在多种癌症中的研究进展及相关作用，其以m6A依赖性或非依赖性的方式通过ID2、lncRNA、CDK1及c-Jun等靶向干细胞因子影响癌细胞的发生、增殖、侵袭、转移和抗凋亡。KIAA1429在不同恶性肿瘤中的致癌作用以及KIAA1429促进癌症发生发展的机制为恶性肿瘤的治疗提供了一定的方向，恢复m6A甲基化的理想水平而纠正KIAA1429在癌症中的表达将可能成为治疗的关键。
Abstract: N6-methyladenine (m6A) modification is one of the most common internal modifications on eukar-yotic messenger RNA (mRNA), and it is also involved in various RNA-related functions, especially plays an important role in the occurrence and development of human malignant tumors. As a dy-namic and reversible modification, the expression level of m6A is co-regulated by m6A methyl-transferases, demethylases and m6A-binding proteins. The methyltransferases that have been dis-covered so far mainly include METTL3, METTL14, KIAA1429 (VIRMA), WTAP and so on. At present, many literatures have reported that m6A methyltransferase KIAA1429 can promote the progres-sion of cancer, and has a certain correlation with the low survival rate of cancer, such as breast can-cer, hepatocellular carcinoma and renal cell carcinoma. This paper summarizes the research pro-gress and related roles of KIAA1429 in various cancers. It affects the occurrence, proliferation, pro-liferation, differentiation and progression of cancer cells through targeting stem cell factors such as ID2, lncRNA, CDK1 and c-Jun in an mA-dependent or independent manner. The oncogenic role of KIAA1429 in different malignant tumors and the mechanism by which KIAA1429 promotes the occurrence and development of cancer provide a certain direction for the treatment of malignant tumors. Restoring the ideal level of m6A methylation and correcting the expression of KIAA1429 in cancer may become the key to treatment.
文章引用：王昊, 吴若卿, 李铀, 肖辉. m6A甲基转移酶KIAA1429在恶性肿瘤中的作用及研究进展[J]. 临床医学进展, 2022, 12(5): 3985-3993. https://doi.org/10.12677/ACM.2022.125578

参考文献

[1] Dominissini, D., Moshitch-Moshkovitz, S., Schwartz, S., et al. (2012) Topology of the Human and Mouse m6A RNA Methylomes Revealed by m6A-seq. Nature, 485, 201-206. [Google Scholar] [CrossRef] [PubMed]
[2] Wang, X., Zhao, B.S., Roundtree, I.A., et al. (2015) N6-Methyladenosine Modulates Messenger RNA Translationefficiency. Cell, 161, 1388-1399. [Google Scholar] [CrossRef] [PubMed]
[3] Wu, Y., Yang, X., Chen, Z., et al. (2019) m6A-Induced lncRNA RP11 Triggers the Dissemination of Colorectal Cancer Cells via Upregulation of Zeb1. Molecular Cancer, 18, Article No. 87. [Google Scholar] [CrossRef] [PubMed]
[4] Han, J., Wang, J.Z., Yang, X., et al. (2019) METTL3 Promote Tumor Proliferation of Bladder Cancer by Accelerating Pri-miR221/222 Maturation in m6A-Dependent Manner. Molecular Cancer, 18, 110. [Google Scholar] [CrossRef] [PubMed]
[5] Zhu, W., Si, Y., Xu, J., et al. (2020) Methyl-Transferase like 3 Promotes Colorectal Cancer Proliferation by Stabilizing CCNE1 mRNA in an m6A-Dependent Manner. Cellular and Molecular Medicine, 24, 3521-3533. [Google Scholar] [CrossRef] [PubMed]
[6] Zhao, X., Yang, Y., Sun, B.F., et al. (2014) FTO-Dependent Demethyla-tion of N6-Methyladenosine Regulates mRNA Splicing and Is Required for Adipogenesis. Cell Research, 24, 1403-1419. [Google Scholar] [CrossRef] [PubMed]
[7] Luo, G.Z., MacQueen, A., Zheng, G., et al. (2014) Unique Features of the m6A Methylome in Arabidopsis Thaliana. Nature Communications, 5, Article No. 5630. [Google Scholar] [CrossRef] [PubMed]
[8] Zhu, W., Wang, J.Z., Xu, Z., et al. (2019) Detection of N6methyladenosine Modification Residues (Review). International Journal of Molecular Medicine, 43, 2267-2278. [Google Scholar] [CrossRef] [PubMed]
[9] Ping, X.L., Sun, B.F., Wang, L., et al. (2014) Mammalian WTAP Is a Regulatory Subunit of the RNA N6-Methyla- denosine Methyltransferase. Cell Research, 24, 177-189. [Google Scholar] [CrossRef] [PubMed]
[10] Zhu, W., Wang, J.Z., Wei, J.F., et al. (2021) Role of m6A Methyltransferase Component VIRMA in Multiple Human cancers (Review). Cancer Cell International, 7, Article No. 172. [Google Scholar] [CrossRef] [PubMed]
[11] Qian, J.Y., Gao, J., Sun, X., et al. (2019) KIAA1429 acts as an Oncogenic Factor in Breast Cancer by Regulating CDK1 in an N6-Methyladenosine-Independent Manner. Oncogene, 38, 6123-6141. [Google Scholar] [CrossRef] [PubMed]
[12] Pendleton, K.E., Chen, B., Liu, K., et al. (2017) The U6 snRNA m6A Methyltransferase METTL16 Regulates SAM Synthetase Intron Retention. Cell, 169, 824-835.E14. [Google Scholar] [CrossRef] [PubMed]
[13] Knuckles, P., Lence, T., Haussmann, I.U., et al. (2018) Zc3h13/Flacc Is Required for Adenosine Methylation by Bridging the mRNA-Binding Factor Rbm15/ Spenito to the m6A Machinery Component Wtap/Fl(2)d. Genes & Development, 32, 415-429. [Google Scholar] [CrossRef] [PubMed]
[14] Deng, X., Su, R., Weng, H., et al. (2018) RNA N6-Methyladenosine Modification in Cancers: Current Status and Perspectives. Cell Research, 28, 507-517. [Google Scholar] [CrossRef] [PubMed]
[15] Ruzicka, K., Zhang, M., Campilho, A., et al. (2017) Identification of Factors Required for m6 A mRNA Methylation in Arabidopsis Reveals a Role for the Conserved E3 Ubiquitin Ligase HAKAI. New Phytologist, 215, 157-172. [Google Scholar] [CrossRef] [PubMed]
[16] Chen, T., Hao, Y.J., Zhang, Y., et al. (2015) m6A RNA Methylation Is Regulated by MicroRNAs and Promotes Reprogramming to Pluripotency. Cell Stem Cell, 16, 289-301. [Google Scholar] [CrossRef] [PubMed]
[17] Geula, S., Moshitch-Moshkovitz, S., Dominissini, D., et al. (2015) Stem Cells. m6A mRNA Methylation facilitates Resolution of Naive Pluripotency toward Differentiation. Science, 347, 1002-1006. [Google Scholar] [CrossRef] [PubMed]
[18] Fustin, J.M., Kojima, R., Itoh, K., et al. (2018) Two Ck1delta Tran-scripts Regulated by m6A Methylation Code for Two Antagonistic Kinases in the Control of the Circadian Clock. Cell Bi-ology, 115, 5980-5985. [Google Scholar] [CrossRef] [PubMed]
[19] Lan, T., Li, H., Zhang, D., Xu, L., et al. (2019) KIAA1429 Contrib-utes to Liver Cancer Progression through N6-me- thyl-0denosine-Dependent Post-Transcriptional Modification of GATA3. Molecular Cancer, 18, Article No. 186. [Google Scholar] [CrossRef] [PubMed]
[20] Miao, R., Dai, C.C., Mei, L., et al. (2020) KIAA1429 Regulates Cell Proliferation by Targeting C-Jun Messenger RNA-Directly in Gastric Cancer. Journal of Cellular Physiology, 235, 7420-7432. [Google Scholar] [CrossRef] [PubMed]
[21] Yang, D.S., Chang, S., Li, F.C., et al. (2021) m6A Transferase KIAA1429-Stabilized LINC00958 Accelerates Gastric Cancer Aerobic Glycolysis through Targeting GLUT1. IUBMB Life, 73, 1325-1333. [Google Scholar] [CrossRef] [PubMed]
[22] Paramasivam, A., George, R. and Vijayashree Pri-yadharsini, J. (2021) Aberrations of m6A Regulators Are Associated with Tumorigenesis and Metastasis in Head and Neck Squamous Cell Carcinoma. Archives of Oral Biology, 122, Article ID: 105030. [Google Scholar] [CrossRef] [PubMed]
[23] Lobo, J., Costa, A.L., Cantante, M., et al. (2019) m6A RNA Modification and Its Writer/Reader VIRMA/YTHDF3 in Testicular Germ Cell Tumors: A Role in Seminoma Phenotype Maintenance. Journal of Translational Medicine, 17, Article No. 79. [Google Scholar] [CrossRef] [PubMed]
[24] Horiuchi, K., Kawamura, T., Iwanari, H., et al. (2013) Identifica-tion of Wilms’ Tumor 1-Associating Protein Complex and Its Role in Alternative Splicing and the Cell Cycle. Biological Chemistry, 288, 33292-33302. [Google Scholar] [CrossRef] 
[25] Wen, J., Lv, R., Ma, H., et al. (2018) Zc3h13 Regulates Nuclear RNA m6A Methylation and Mouse Embryonic Stem Cell Self-Renewal. Molecular Cancer, 69, 1028-1038.E6. [Google Scholar] [CrossRef] [PubMed]
[26] Yue, Y., Liu, J., Cui, X., et al. (2018) VIRMA Mediates Prefer-ential m6A mRNA Methylation in 3’UTR and near Stop Codon and Associates with Alternative Polyadenylation. Cell Discovery, 4, Article No. 10. [Google Scholar] [CrossRef] [PubMed]
[27] Li, Y.K., Xiao, J., Bai, J., et al. (2019) Molecular Characterization and Clinical Relevance of m6A Regulators across 33 Cancer Types. Molecular Cancer, 18, Article No. 137. [Google Scholar] [CrossRef] [PubMed]
[28] XU, D., SHAO, J., SONG, H., et al. (2020) The YTH Domain Family of N6-Methyladenosine“Readers”in the Diagnosis and Prognosis of Colonic Adenocarcinoma. BioMed Research International, 2020, Article ID: 9502560. [Google Scholar] [CrossRef] [PubMed]
[29] Liu, L., Liu, X., Dong, Z., et al. (2019) N6-Methyladenosine-Related Genomic Targets Are Altered in Breast Cancer Tissue and Associated with Poor Survival. Cancer, 10, 5447-5459. [Google Scholar] [CrossRef] [PubMed]
[30] Cheng, X., Li, M., Rao, X., et al. (2019) KIAA1429 Regulates the Migra-tion and Invasion of Hepatocellular Carcinoma by Altering m6A Modification of ID2 mRNA. OncoTargets and Thera-py, 12, 3421-3428. [Google Scholar] [CrossRef] 
[31] Wang, Y.Z., Ren, F., Song, Z.X., et al. (2020) Multiomics Profile and Prognostic Gene Signature of m6A Regulators in Uterine Corpus Endometrial Carcinoma. Journal of Cancer, 11, 6390-6401. [Google Scholar] [CrossRef] [PubMed]
[32] Li, F.W., Wang, H., Huang, H.R., et al. (2020) m6A RNA Methylation Regulators Participate in the Malignant Progression and Have Clinical Prognostic Value in Lung Adenocar-cinoma. Frontiers in Genetics, 11, Article No. 994. [Google Scholar] [CrossRef] [PubMed]
[33] Zhao, H.Y., Xu, Y., Xie, Y.L., et al. (2021) m6A Regulators Is Differently Expressed and Correlated with Immune Response of Esophageal Cancer. Frontiers in Cell and Developmen-tal Biology, 9, Article ID: 650023. [Google Scholar] [CrossRef] [PubMed]
[34] Lobo, J., Barros-Silva, D., Henrique, R., et al. (2018) The Emerging role of Epitranscriptomics in Cancer: Focus on Urological Tumors. Genes, 9, Article No. 552. [Google Scholar] [CrossRef] [PubMed]
[35] Fan, L., Lin, Y., Lei, H., et al. (2020) A Newly Defined Risk Signature, Consisting of Three m6A RNA Methylation Regulators, Predicts the Prognosis of Ovarian Cancer. Aging, 12, 18453-18475. [Google Scholar] [CrossRef] [PubMed]
[36] Hou, J., Shan, H., Zhang, Y., et al. (2020) m6A RNA Methylation Regulators Have Prognostic Value in Papillary Thyroid Carcinoma. American Journal of Otolaryngology, 41, Article ID: 102547. [Google Scholar] [CrossRef] [PubMed]
[37] Qu, N., Qin, S., Zhang, X., et al. (2020) Multiple m6 A RNA Methylation Modulators Promote the Malignant Progression of Hepatocellular Carcinoma and Affect Its Clinical Progno-sis. BMC Cancer, 20, Article No. 165. [Google Scholar] [CrossRef] [PubMed]
[38] Wang, M., Yang, Y., Yang, J., et al. (2020) Circ_KIAA1429 Accelerates Hepatocellular Carcinoma Advancement through the Mechanism of m6 A-YTHDF3-Zeb1. Life Sciences, 257, Article ID: 118082. [Google Scholar] [CrossRef] [PubMed]
[39] Chen, M., Nie, Z.Y., Wen, X.H., et al. (2019) m6A RNA Methyla-tion Regulators Can Contribute to Malignant Progression and Impact the Prognosis of Bladder Cancer. Bioscience Re-ports, 39, Article ID: BSR20192892. [Google Scholar] [CrossRef] 
[40] Sun, Z., Jing, C., Xiao, C., et al. (2020) Prognostic Risk Signature Based on the Expression of Three m6A RNA Methylation Regulatory Genes in Kidney Renal Papillary Cell Carcinoma. Aging, 12, 22078-22094. [Google Scholar] [CrossRef] [PubMed]
[41] Tsunedomi, R., Iizuka, N., Tamesa, T., et al. (2008) Decreased ID2 Promotes Metastatic Potentials of Hepatocellular Carcinoma by Altering Secretion of Vascular Endothelial Growth Fac-tor. Clinical Cancer Research, 14, 1025-1031. [Google Scholar] [CrossRef] 
[42] Lasorella, A., Benezra, R. and Iavarone, A. (2014) The ID Proteins: Master Regulators of Cancer Stem Cells and Tumour Aggressiveness. Nature Reviews Cancer, 14, 77-91. [Google Scholar] [CrossRef] [PubMed]
[43] Havrda, M.C., Paolella, B.R., Ran, C., et al. (2014) Id2 Mediates Oligoden-drocyte Precursor Cell Maturation Arrest and Is Tumorigenic in a PDGF-Rich Microenvironment. Cancer Research, 74, 1822-1832. [Google Scholar] [CrossRef] 
[44] Jacob, R., Zander, S. and Gutschner, T. (2018) The Dark Side of the Epitranscriptome: Chemical Modifications in Long Non-Coding RNAs. International Journal of Molecular Sciences, 18, Article No. 2387. [Google Scholar] [CrossRef] [PubMed]
[45] Barros-Silva D, Lobo, J., Guimarães-Teixeira, C., et al. (2020) VIRMA-Dependent N6-Methyladenosine Modifications Regulate the Expression of Long Non-Coding RNAs CCAT1 and CCAT2 in Prostate Cancer. Cancers, 12, Article No. 771. [Google Scholar] [CrossRef] [PubMed]
[46] Barros-Silva, D. and Costa-Pinheiro, P. (2018) Duarte HMi-croRNA-27a-5p Regulation by Promoter Methylation and MYC Signaling in Prostate Carcinogenesis. Cell Death & Disease, 9, Article No. 167. [Google Scholar] [CrossRef] [PubMed]
[47] Hamilton, M.J., Young, M.D., Sauer, S., et al. (2015) The Inter-play of Long Non-Coding RNAs and MYC in Cancer. Aims Biophysics, 2, 794-809. [Google Scholar] [CrossRef] [PubMed]
[48] Zhuang, K., Wu, Q., Jiang, S., et al. (2016) CCAT1 Promotes Laryngeal Squamous Cell Carcinoma Cell Proliferation and Invasion. American Journal of Translational Research, 8, 4338-4345.
[49] Yu, Y., Nangia-Makker, P., Farhana, L., et al. (2017) A Novel Mechanism of lncRNA and miRNA Interaction: CCAT2 Regulates miR-145 Expression by Suppressing Its Maturation Process in Colon Cancer Cells. Mo-lecular Cancer, 16, Article No. 155. [Google Scholar] [CrossRef] [PubMed]

为你推荐